Clinical trials: FLU
Influenza (Pandemic), Avian Influenza
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the…
- Conditions
- Influenza (Pandemic), Avian Influenza, Vaccination
- Trial name
- PIVOT (NCT07240558)
- Testing
- H5N1 vaccine (Arepanrix, GSK)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014 Northern Hemisphere, in adults ≥65 years of…
- Trial name
- NCT01879540
- Testing
- aTIV
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
H1ssF Flu Vaccine Clinical Trial
This is a two-arm, open-label, randomized, phase 1, controlled clinical trial intended to evaluate the safety and immunologic response to the experimental vaccine H1ssF (H1 stabilized stem ferritin nanoparticle) and the seasonal…
- Trial name
- NCT07340047
- Testing
- H1ssF vaccine, Flucelvax seasonal vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Influenza
Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, and a 6 month booster dose, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza…
- Trial name
- NCT00382187
- Testing
- MF59 adjuvanted H5N1 influenza vaccine
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Respiratory Infections, Antibiotic
Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).
- Trial name
- TROD-VILLE (NCT07243249)
- Testing
- TROD
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)
The purpose of this randomized, double-blind, placebo-controlled trial of intravenous hyperimmune immunoglobulin (Flu-IVIG) in individuals with influenza A or B is to determine the pharmacokinetic (PK) profile of Flu-IVIG and…
- Trial name
- NCT02008578
- Testing
- Intravenous hyperimmune immunoglobulin (Flu-IVIG)
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Combining Entertainment & Influenza Education for Pediatric Patients
The investigators have developed an influenza-vaccination-education-study-program that will involve the use of an animated influenza vaccine-based computer program (videogame) that is designed from the investigator's own…
- Trial name
- NCT01788514
- Testing
- Videogame
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Influenza
Study of the Safety and Immunogenicity of NasoVAX Extension
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
- Trial name
- NCT03760549
- Testing
- Subjects were administered NasoVAX high dose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
- Trial name
- NCT00192140
- Testing
- FluMist
- Where
- 11 sites in United States
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Retrospective, Observational Registry of Participants With Avian Influenza Infection
This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1.
- Trial name
- NCT02743676
- Volunteers
- 648 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged 18 years or older.
- Trial name
- NCT01857297
- Testing
- Enzira® vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
FLU-v is a vaccine that aims to protect against a wide range of flu viruses. The purpose of this study is to measure the immune responses induced by FLU-v vaccine.
- Trial name
- NCT02962908
- Testing
- FLU-v, adjuvanted FLU-v, Saline
- Where
- Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with the Viroflu® seasonal influenza vaccine.
- Trial name
- NCT02014168
- Testing
- Viroflu® and MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza, Human
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Background: Vaccines are substances used to try to create resistance or immunity to a disease and to prevent an infection. Investigators are looking into improved ways to give and test the results of different kinds of vaccines.
- Trial name
- NCT00995982
- Testing
- VRC-FLUDNA056-00VP
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Immunization; Infection, Influenza
Seasonal Influenza and Pneumococcal Vaccination in the Elderly
The elderly population and individuals with chronic diseases are at high risk for influenza and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza vaccine together is effective in reducing…
- Conditions
- Immunization; Infection, Influenza, Pneumonia, Vaccine Refusal
- Trial name
- NCT05661890
- Where
- Turkey (Türkiye)
- Volunteers
- 1,166 people
- Sponsor
- Lokman Hekim University
Vaccine Preventable Diseases, Meningococcal Disease
Testing the Use of Prompts to Increase Adolescent Immunization Rates
Although most US adolescents visit their primary care doctor, their immunization rates are low. Primary care practices from two networks, one in upstate New York as well as a national network of pediatric clinics were surveyed to…
- Conditions
- Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis
- Trial name
- AIMHi (NCT01984125)
- Testing
- Point-of-Care Prompt
- Where
- 22 sites in United States
- Volunteers
- 7,040 people
- Sponsor
- University of California, Los Angeles
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.